Table 1.
Patient Demographic and Disease Characteristics
| Variable | TAE-iNKT (N = 27) | TAE (N=27) |
|---|---|---|
| Median size of HCC(IQR), mm | 64.78 (35.95–107.36) | 68.90 (42.20–103.20) |
| Median age (IQR), year | 60 (51–69) | 59 (54–63) |
| Sex, N (%) | ||
| Male | 23 (85) | 24 (89) |
| Female | 4 (15) | 3 (11) |
| Cause of hepatocellular carcinoma, N (%) | ||
| Hepatitis B | 23 (85) | 21 (78)a |
| Hepatitis C | 2 (7) | 4 (15) |
| Nonviral | 2 (7) | 3 (11) |
| ECOG performance status score, N (%) | ||
| 0 | 23 (85) | 21 (78) |
| 1 | 4 (15) | 6 (22) |
| Child-Pugh classification, N/total (%) | ||
| A | 21/27 (78) | 24/27 (89) |
| B | 6/27 (22) | 3/27 (11) |
| Barcelona Clinic liver cancer stage, N (%) | ||
| B | 12 (44) | 12 (44) |
| C | 15 (56) | 15 (56) |
| Alpha-fetoprotein >400 ng per milliliter, N (%) | 8 (30) | 5 (19) |
| Presence of macrovascular invasion, extrahepatic spread, or both, N (%) | ||
| Macrovascular invasion | 10 (37) | 13 (48) |
| Extrahepatic spread | 11 (41) | 4 (15) |
| Varices, N (%) | ||
| Present at baseline | 16 (59) | 23 (85) |
| Treated at baseline | 1 (4) | 6 (22) |
| Cirrhosis, N (%) | ||
| Yes | 19 (70) | 17 (63) |
| No | 8 (30) | 10 (37) |
| History of treatment | ||
| TACE (≥2 consecutive procedures), N (%) | 27 (100) | 27 (100) |
| TACE times | 2~12 | 2~6 |
| Systemic treatment, N (%) | 2 (7) | 1 (4) |
| Radiofrequency ablation, N (%) | 9 (33) | 12 (44) |
| Radiotherapy, N (%) | 2 (7) | 0 (0) |
| Resection, N (%) | 7 (26) | 1 (4) |
| Argon-helium knife, N (%) | 2 (7) | 1 (4) |
Notes: aOne patient in the TAE group was co-infected with HBV and HCV.
Abbreviations: TACE, transarterial chemoembolization; TAE, Transarterial embolization; ECOG, Eastern Cooperative Oncology Group.